Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
Anavex Life Sciences (AVXL), a clinical-stage biopharmaceutical firm focusing on treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric conditions, announced its participation in the H.C. Wainwright 2nd BioConnect Investor Conference. The event will occur on May 20, 2024, at 10:00am ET at NASDAQ World Headquarters in New York City.
Christopher U. Missling, PhD, Anavex's President and CEO, will engage in a fireside chat. A live audio webcast will be available on the company's website, with an archived version accessible later.
- Participation in a prominent investor conference at NASDAQ could enhance visibility and investor interest.
- The CEO's involvement in a fireside chat may provide valuable insights into the company’s strategic direction and ongoing projects.
- No new financial or clinical data was disclosed, which may leave investors seeking more concrete updates.
- The impact of this event on stock performance is uncertain, as it primarily serves as a platform for discussion rather than delivering actionable news or results.
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ being held May 20th, 2024 at 10:00am ET at NASDAQ World Headquarters New York City.
A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
What event is Anavex Life Sciences participating in on May 20, 2024?
Who will represent Anavex Life Sciences at the H.C. Wainwright 2nd BioConnect Investor Conference?
What is the significance of Anavex Life Sciences' participation in the H.C. Wainwright 2nd BioConnect Investor Conference?
Where can I access the live audio webcast of Anavex Life Sciences at the H.C. Wainwright 2nd BioConnect Investor Conference?
Will there be a recording available of Anavex Life Sciences' presentation at the conference?
